Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007))

F. I. Mulder; N. van Es; N. Kraaijpoel; M. di Nisio; M. Carrier; A. Duggal; M. Gaddh; D. Garcia; M. A. Grosso; A. K. Kakkar; M. F. Mercuri; S. Middeldorp; G. Royle; A. Segers; S. Shivakumar; P. Verhamme; T. Wang; J. I. Weitz; G. Zhang; H. R. Büller; G. Raskob

doi:https://doi.org/10.1016/j.thromres.2020.02.022

Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007))

F. I. Mulder, N. van Es, N. Kraaijpoel, M. di Nisio, M. Carrier, A. Duggal, M. Gaddh, D. Garcia, M. A. Grosso, A. K. Kakkar, M. F. Mercuri, S. Middeldorp, G. Royle, A. Segers, S. Shivakumar, P. Verhamme, T. Wang, J. I. Weitz, G. Zhang, H. R. BüllerG. Raskob

Research output: Contribution to journal › Erratum/Corrigendum › Academic

2 Citations (Scopus)

Abstract

The authors regret that panel E of Fig. 1 was missing, showing the cumulative incidence of the primary outcome in hematologic cancer. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	156-159
Number of pages	4
Journal	Thrombosis research
Volume	191
DOIs	https://doi.org/10.1016/j.thromres.2020.02.022
Publication status	Published - Jul 2020

Access to Document

https://doi.org/10.1016/j.thromres.2020.02.022

Cite this

Mulder, F. I., van Es, N., Kraaijpoel, N., di Nisio, M., Carrier, M., Duggal, A., Gaddh, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Mercuri, M. F., Middeldorp, S., Royle, G., Segers, A., Shivakumar, S., Verhamme, P., Wang, T., Weitz, J. I., Zhang, G., ... Raskob, G. (2020). Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007)). Thrombosis research, 191, 156-159. https://doi.org/10.1016/j.thromres.2020.02.022

Mulder, F. I. ; van Es, N. ; Kraaijpoel, N. et al. / Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer : Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007)). In: Thrombosis research. 2020 ; Vol. 191. pp. 156-159.

@article{3de80439443941bc8d80fe363e16266f,

title = "Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007))",

abstract = "The authors regret that panel E of Fig. 1 was missing, showing the cumulative incidence of the primary outcome in hematologic cancer. The authors would like to apologise for any inconvenience caused.",

author = "Mulder, {F. I.} and {van Es}, N. and N. Kraaijpoel and {di Nisio}, M. and M. Carrier and A. Duggal and M. Gaddh and D. Garcia and Grosso, {M. A.} and Kakkar, {A. K.} and Mercuri, {M. F.} and S. Middeldorp and G. Royle and A. Segers and S. Shivakumar and P. Verhamme and T. Wang and Weitz, {J. I.} and G. Zhang and B{\"u}ller, {H. R.} and G. Raskob",

year = "2020",

month = jul,

doi = "https://doi.org/10.1016/j.thromres.2020.02.022",

language = "English",

volume = "191",

pages = "156--159",

journal = "Thrombosis research",

issn = "0049-3848",

publisher = "Elsevier Limited",

}

Mulder, FI , van Es, N , Kraaijpoel, N, di Nisio, M, Carrier, M, Duggal, A, Gaddh, M, Garcia, D, Grosso, MA, Kakkar, AK, Mercuri, MF, Middeldorp, S, Royle, G, Segers, A, Shivakumar, S, Verhamme, P, Wang, T, Weitz, JI, Zhang, G, Büller, HR & Raskob, G 2020, 'Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007))', Thrombosis research, vol. 191, pp. 156-159. https://doi.org/10.1016/j.thromres.2020.02.022

Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007)). / Mulder, F. I.; van Es, N.; Kraaijpoel, N. et al.
In: Thrombosis research, Vol. 191, 07.2020, p. 156-159.

Research output: Contribution to journal › Erratum/Corrigendum › Academic

TY - JOUR

T1 - Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer

T2 - Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007))

AU - Mulder, F. I.

AU - van Es, N.

AU - Kraaijpoel, N.

AU - di Nisio, M.

AU - Carrier, M.

AU - Duggal, A.

AU - Gaddh, M.

AU - Garcia, D.

AU - Grosso, M. A.

AU - Kakkar, A. K.

AU - Mercuri, M. F.

AU - Middeldorp, S.

AU - Royle, G.

AU - Segers, A.

AU - Shivakumar, S.

AU - Verhamme, P.

AU - Wang, T.

AU - Weitz, J. I.

AU - Zhang, G.

AU - Büller, H. R.

AU - Raskob, G.

PY - 2020/7

Y1 - 2020/7

N2 - The authors regret that panel E of Fig. 1 was missing, showing the cumulative incidence of the primary outcome in hematologic cancer. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that panel E of Fig. 1 was missing, showing the cumulative incidence of the primary outcome in hematologic cancer. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85081225167&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.thromres.2020.02.022

DO - https://doi.org/10.1016/j.thromres.2020.02.022

M3 - Erratum/Corrigendum

C2 - 32151398

SN - 0049-3848

VL - 191

SP - 156

EP - 159

JO - Thrombosis research

JF - Thrombosis research

ER -

Mulder FI , van Es N , Kraaijpoel N, di Nisio M, Carrier M, Duggal A et al. Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007)). Thrombosis research. 2020 Jul;191:156-159. doi: https://doi.org/10.1016/j.thromres.2020.02.022

Abstract

Access to Document

Other files and links

Cite this